Cargando…
Patient derived organoids to model rare prostate cancer phenotypes
A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of prostate cancer that may arise de novo or as a mechanism of treatment resistance in patients with pre-existing castration-resistant...
Autores principales: | Puca, Loredana, Bareja, Rohan, Prandi, Davide, Shaw, Reid, Benelli, Matteo, Karthaus, Wouter R., Hess, Judy, Sigouros, Michael, Donoghue, Adam, Kossai, Myriam, Gao, Dong, Cyrta, Joanna, Sailer, Verena, Vosoughi, Aram, Pauli, Chantal, Churakova, Yelena, Cheung, Cynthia, Deonarine, Lesa Dayal, McNary, Terra J., Rosati, Rachele, Tagawa, Scott T., Nanus, David M., Mosquera, Juan Miguel, Sawyers, Charles L., Chen, Yu, Inghirami, Giorgio, Rao, Rema A., Grandori, Carla, Elemento, Olivier, Sboner, Andrea, Demichelis, Francesca, Rubin, Mark A., Beltran, Himisha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008438/ https://www.ncbi.nlm.nih.gov/pubmed/29921838 http://dx.doi.org/10.1038/s41467-018-04495-z |
Ejemplares similares
-
Divergent clonal evolution of castration resistant neuroendocrine prostate cancer
por: Beltran, Himisha, et al.
Publicado: (2016) -
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer
por: Brady, Nicholas J., et al.
Publicado: (2021) -
G3BP1 inhibits Cul3(SPOP) to amplify AR signaling and promote prostate cancer
por: Mukhopadhyay, Chandrani, et al.
Publicado: (2021) -
Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage
por: Gjyrezi, Ada, et al.
Publicado: (2021) -
ASEQ: fast allele-specific studies from next-generation sequencing data
por: Romanel, Alessandro, et al.
Publicado: (2015)